去铁胺及其铁和铝螯合物在腹膜透析患者中的药代动力学。

Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.

作者信息

Allain P, Chaleil D, Mauras Y, Varin M C, Ang K S, Cam G, Simon P

机构信息

Laboratoire de Pharmacologie, C.H.U. Angers, France.

出版信息

Clin Chim Acta. 1988 Apr 29;173(3):313-6. doi: 10.1016/0009-8981(88)90019-8.

DOI:10.1016/0009-8981(88)90019-8

PMID:3383431

Abstract

We have studied the pharmacokinetics of desferrioxamine (DFA), ferrioxamine (FeA) and aluminoxamine (AlA) in patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) after 10 mg/kg (15.24 mumol/kg) body weight desferrioxamine (DESFERAL) administration by intramuscular and intraperitoneal routes. The results show an easy exchange of DFA between the plasma and the peritoneal fluid regulated by the relative concentrations of DFA in the two compartments. When the equilibrium is reached, the concentration of DFA are approximately the same in the plasma and the peritoneal fluid.

摘要

我们研究了在持续非卧床腹膜透析（CAPD）的慢性肾衰竭患者中，经肌肉注射和腹腔内途径给予10 mg/kg（15.24 μmol/kg）体重去铁胺（得斯芬）后，去铁胺（DFA）、铁胺（FeA）和铝胺（AlA）的药代动力学。结果表明，DFA在血浆和腹膜液之间易于交换，这由两个隔室中DFA的相对浓度调节。当达到平衡时，血浆和腹膜液中DFA的浓度大致相同。